Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Etigilimab |
Trade Name | |
Synonyms | OMP313M32|OMP 313M32|OMP-313M32|WHO 10742|MPH313 |
Drug Descriptions |
Etigilimab (OMP-313M32) is an anti-human TIGIT (T cell immunoreceptor with Ig ITIM domain) antibody that potentially has anti-tumor activities through modulating the immune response to tumors (AACR, Vol 58, April 2017, Abstract #599, PMID: 31874056). |
DrugClasses | Immune Checkpoint Inhibitor 149 TIGIT Antibody 19 |
CAS Registry Number | 2044984-83-8 |
NCIT ID | C142821 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Etigilimab | Etigilimab | 0 | 1 |
Etigilimab + Nivolumab | Etigilimab Nivolumab | 0 | 2 |